ArticleNPJ precision oncology2023
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Yuki Katayama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papercites it
ArticleNPJ precision oncology2023
Yuki Katayama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.